🔥 Acute Gout Flare Treatment Simulator

MSU Crystal-Triggered Neutrophil Influx

Urate crystals precipitate in the joint and recruit neutrophils fast.

• >6.8 mg/dL: Serum urate threshold (saturation point)
• Needle-like: Crystal shape (monosodium urate)
• 2–6 h: Neutrophil influx onset (from first symptom)
• 12–24 h: Peak flare intensity (typical timing)

Crystal deposition

Cooling joints let urate crystallize out of supersaturated synovial fluid.

Innate immune recognition

Resident macrophages sense crystals via NLRP3 and release IL-1β.

Neutrophil recruitment

Chemokines draw circulating neutrophils rapidly into the joint space.

Choosing Colchicine, NSAID, or Glucocorticoid

Drug choice depends heavily on how long symptoms have lasted.

• <36 h: Colchicine window (best efficacy early)
• <48–72 h: NSAID window (broad effective range)
• Any time: Glucocorticoid window (reliable regardless of delay)
• Steroid preferred: Renal-impaired option (avoids NSAID/colchicine risk)

Timing drives efficacy

Colchicine loses potency the longer treatment is delayed.

Comorbidity constraints

Kidney disease often rules out NSAIDs and colchicine dosing.

Steroid flexibility

Glucocorticoids work well even when the flare is late.

Suppressing the Inflammatory Cascade

The chosen drug interrupts crystal-driven inflammatory signaling.

• Indirect: IL-1β blockade (via NLRP3 pathway)
• Reduced: Neutrophil chemotaxis (colchicine mechanism)
• Blocked: Prostaglandin synthesis (NSAID mechanism)
• Suppressed: Gene transcription (glucocorticoid mechanism)

Colchicine mechanism

Colchicine disrupts microtubules, halting neutrophil movement into the joint.

NSAID mechanism

NSAIDs block COX enzymes, cutting prostaglandin-driven pain and swelling.

Glucocorticoid mechanism

Steroids broadly suppress inflammatory gene expression within hours.

Pain and Swelling Resolution Over Time

Pain and swelling decline steadily once treatment takes hold.

• ~50%: Pain reduction (24h) (with early treatment)
• ~24–48 h: Swelling half-life (treated flare)
• 7–14 d: Untreated resolution (natural course)
• 2–5 d: Treated resolution (typical range)

Pain curve

Pain scores fall fastest in the first two treated days.

Swelling lag

Joint swelling resolves slightly slower than reported pain.

Dose-response

Earlier treatment consistently shortens the overall recovery curve.

Flare Resolved vs Delayed-Treatment Course

Early treatment resolves flares far faster than delayed care.

• ~48 h: Treated within 12h (to resolution)
• ~5–7 d: Treated after 48h (to resolution)
• 7–14 d: Untreated flare (natural course)
• ~60%: Recurrence risk (within 1 yr, untreated hyperuricemia)

Fast-track resolution

Prompt treatment shortens flares to roughly two days.

Delayed course

Late treatment still helps but recovery drags on.

Long-term control

Urate-lowering therapy afterward prevents future recurrent flares.